Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zorifertinib + furmonertinib for leptomeningeal metastases after 3rd-generation EGFR-TKI resistance in EGFR-mutant NSCLC
ChiCTR2500110040Phase 2Not yet recruiting
- Sponsor
- Affiliated Brain Hospital of Nanjing Medical University
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zorifertinib and furmonertinib in non-small cell lung cancer (NSCLC) and Carcinomatous Meningitis (CM), sponsored by Affiliated Brain Hospital of Nanjing Medical University. Primary endpoint: Leptomeningeal progression-free survival (LmPFS). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
zorifertinibfurmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)Carcinomatous Meningitis (CM)
Beyond the preview
Go deeper on ChiCTR2500110040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110040.